Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) FCF Margin (2016 - 2025)

Vanda Pharmaceuticals' FCF Margin history spans 16 years, with the latest figure at 51.59% for Q4 2025.

  • For Q4 2025, FCF Margin fell 4777.0% year-over-year to 51.59%; the TTM value through Dec 2025 reached 51.1%, down 4293.0%, while the annual FY2025 figure was 51.1%, 4293.0% down from the prior year.
  • FCF Margin for Q4 2025 was 51.59% at Vanda Pharmaceuticals, up from 56.5% in the prior quarter.
  • Across five years, FCF Margin topped out at 50.8% in Q1 2023 and bottomed at 67.11% in Q1 2025.
  • The 5-year median for FCF Margin is 1.39% (2022), against an average of 4.33%.
  • The largest annual shift saw FCF Margin skyrocketed 4421bps in 2023 before it tumbled -8304bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 38.92% in 2021, then crashed by -64bps to 14.19% in 2022, then tumbled by -162bps to 8.8% in 2023, then surged by 57bps to 3.82% in 2024, then plummeted by -1251bps to 51.59% in 2025.
  • Per Business Quant, the three most recent readings for VNDA's FCF Margin are 51.59% (Q4 2025), 56.5% (Q3 2025), and 29.57% (Q2 2025).